Ziltivekimab (IL-6 inhibitor) for MMN — Evidence & Clinical Trials

Overview

Treatment Details

Mechanism of Action

Investigational human monoclonal antibody targeting interleukin-6 (IL-6), a central mediator of vascular inflammation and atherosclerotic plaque progression. The Phase 2 RESCUE trial showed significant reductions in inflammatory biomarkers (hsCRP, IL-6, fibrinogen) in high-cardiovascular-risk patients with CKD. Phase 3 cardiovascular outcomes trial (ZEUS) ongoing.

Dosing Notes

Investigational; subcutaneous injection. Dose under evaluation in Phase 3.

Treatment Type

pharmaceutical

Clinical Evidence

What the Evidence Shows

Each finding below is linked to its primary source. Confidence levels reflect the quality and quantity of available evidence — not CelluTarget's endorsement of any treatment.

High: Supported by multiple robust studies or regulatory approval

Moderate: Supported by limited controlled studies or consistent case series

Low: Based on case reports, expert opinion, or early-phase data only

Low ConfidenceBased on case reports, expert opinion, or early-phase data only

Phase 2 RESCUE trial: ziltivekimab significantly reduced hsCRP, IL-6, fibrinogen, and other inflammatory biomarkers in patients with atherosclerotic disease and CKD. Phase 3 ZEUS outcomes trial ongoing — definitive cardiovascular event data not yet available.

Verified Jul 2026

Peer Reviewed

Inflammation in atherosclerotic cardiovascular disease: From diagnosis to treatment (PMC 2026)

Published January 2026

View source ↗

Clinical Trials

Linked Trials1 trial

No registry ID — unregistered program

MACE composite in high-risk patients with elevated hsCRP and chronic kidney disease

Target enrollment: 6000 participants